JP2003517423A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003517423A5 JP2003517423A5 JP2000504866A JP2000504866A JP2003517423A5 JP 2003517423 A5 JP2003517423 A5 JP 2003517423A5 JP 2000504866 A JP2000504866 A JP 2000504866A JP 2000504866 A JP2000504866 A JP 2000504866A JP 2003517423 A5 JP2003517423 A5 JP 2003517423A5
- Authority
- JP
- Japan
- Prior art keywords
- adenosine
- ethyluronamide
- substituted
- alkyl
- echiruuronamido
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- -1 amino, substituted amino Chemical group 0.000 description 27
- 150000001875 compounds Chemical class 0.000 description 12
- 229910052739 hydrogen Inorganic materials 0.000 description 7
- 239000001257 hydrogen Substances 0.000 description 7
- 239000000556 agonist Substances 0.000 description 6
- 239000004031 partial agonist Substances 0.000 description 6
- 125000000217 alkyl group Chemical group 0.000 description 5
- 125000003118 aryl group Chemical group 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 125000000547 substituted alkyl group Chemical group 0.000 description 4
- 125000005309 thioalkoxy group Chemical group 0.000 description 4
- 125000003545 alkoxy group Chemical group 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 125000001475 halogen functional group Chemical group 0.000 description 3
- 125000001072 heteroaryl group Chemical group 0.000 description 3
- 150000002431 hydrogen Chemical group 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 206010021143 Hypoxia Diseases 0.000 description 2
- 125000002252 acyl group Chemical group 0.000 description 2
- 125000004442 acylamino group Chemical group 0.000 description 2
- 125000004423 acyloxy group Chemical group 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 125000003342 alkenyl group Chemical group 0.000 description 2
- 125000002877 alkyl aryl group Chemical group 0.000 description 2
- 125000000304 alkynyl group Chemical group 0.000 description 2
- 125000004104 aryloxy group Chemical group 0.000 description 2
- 125000004181 carboxyalkyl group Chemical group 0.000 description 2
- 125000004093 cyano group Chemical group *C#N 0.000 description 2
- 125000005553 heteroaryloxy group Chemical group 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- 230000007954 hypoxia Effects 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 125000005017 substituted alkenyl group Chemical group 0.000 description 2
- 125000005415 substituted alkoxy group Chemical group 0.000 description 2
- 125000004426 substituted alkynyl group Chemical group 0.000 description 2
- 229940124530 sulfonamide Drugs 0.000 description 2
- 125000005296 thioaryloxy group Chemical group 0.000 description 2
- 125000005404 thioheteroaryloxy group Chemical group 0.000 description 2
- 125000004953 trihalomethyl group Chemical group 0.000 description 2
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 208000031229 Cardiomyopathies Diseases 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000003734 Supraventricular Tachycardia Diseases 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000005961 cardioprotection Effects 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 230000004112 neuroprotection Effects 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 201000002859 sleep apnea Diseases 0.000 description 1
- 125000003107 substituted aryl group Chemical group 0.000 description 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 1
- 150000007970 thio esters Chemical class 0.000 description 1
- 150000003568 thioethers Chemical class 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 206010047302 ventricular tachycardia Diseases 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US5406497P | 1997-07-29 | 1997-07-29 | |
| US60/054,064 | 1997-07-29 | ||
| PCT/US1998/016053 WO1999006053A1 (en) | 1997-07-29 | 1998-07-29 | N6-substituted-adenosine-5'-uronamides as adenosine receptor modulators |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2003517423A JP2003517423A (ja) | 2003-05-27 |
| JP2003517423A5 true JP2003517423A5 (cg-RX-API-DMAC7.html) | 2006-01-05 |
Family
ID=21988552
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000504866A Pending JP2003517423A (ja) | 1997-07-29 | 1998-07-29 | アデノシンレセプターモジュレーターとしてのn6−置換アデノシン−5′−ウロナミド |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP1019427A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2003517423A (cg-RX-API-DMAC7.html) |
| AU (1) | AU8764398A (cg-RX-API-DMAC7.html) |
| CA (1) | CA2296485A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO1999006053A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998050047A1 (en) * | 1997-05-09 | 1998-11-12 | Trustees Of The University Of Pennsylvania | Methods and compositions for reducing ischemic injury of the heart by administering adenosine receptor agonists and antagonists |
| HUP0103836A3 (en) | 1998-06-02 | 2003-05-28 | Osi Pharmaceuticals Inc Uniond | Pyrrolo[2,3d]pyrimidine compositions and their use |
| US6878716B1 (en) | 1998-06-02 | 2005-04-12 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A1 receptor and uses thereof |
| US6686366B1 (en) | 1998-06-02 | 2004-02-03 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A3 receptor and uses thereof |
| IL133680A0 (en) * | 1999-09-10 | 2001-04-30 | Can Fite Technologies Ltd | Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist |
| US6664252B2 (en) | 1999-12-02 | 2003-12-16 | Osi Pharmaceuticals, Inc. | 4-aminopyrrolo[2,3-d]pyrimidine compounds specific to adenosine A2a receptor and uses thereof |
| US6680322B2 (en) | 1999-12-02 | 2004-01-20 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A1 receptors and uses thereof |
| US7160890B2 (en) | 1999-12-02 | 2007-01-09 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A3 receptor and uses thereof |
| ES2269217T3 (es) | 1999-12-02 | 2007-04-01 | Osi Pharmaceuticals, Inc. | Compuestos especificos para los receptores a1, a2a y a3 de adenosina y sus usos. |
| WO2002035231A1 (en) * | 2000-10-26 | 2002-05-02 | Actar Ab | Screening method using a g coupled receptor associated with a specific g protein |
| US6680324B2 (en) | 2000-12-01 | 2004-01-20 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A1 receptors and uses thereof |
| US6673802B2 (en) | 2000-12-01 | 2004-01-06 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A3 receptor and uses thereof |
| CA2434906C (en) | 2001-01-16 | 2008-08-19 | Can-Fite Biopharma Ltd. | Use of an adenosine a3 receptor agonist for inhibition of viral replication |
| US20020115635A1 (en) * | 2001-02-21 | 2002-08-22 | Pnina Fishman | Modulation of GSK-3beta activity and its different uses |
| JP2005529062A (ja) | 2001-11-30 | 2005-09-29 | オーエスアイ・ファーマスーティカルズ・インコーポレーテッド | アデノシンa1及びa3受容体に特異的な化合物とその使用 |
| DE60236458D1 (de) | 2001-12-20 | 2010-07-01 | Osi Pharm Inc | Pyrrolopyrimidin a2b selektive antagonistische verbindungen, deren synthese und verwendung |
| KR20040068317A (ko) | 2001-12-20 | 2004-07-30 | 오에스아이 파마슈티컬스, 인코포레이티드 | 피리미딘 a₂b 선택성 길항 화합물, 그의 합성 방법 및용도 |
| GB0228723D0 (en) | 2002-12-09 | 2003-01-15 | Cambridge Biotechnology Ltd | Treatment of pain |
| DE602004027409D1 (de) * | 2003-10-21 | 2010-07-08 | Inspire Pharmaceuticals Inc | Tetrahydrofuroä3,4-düdioxolverbindungen und zusammensetzungen und verfahren zur inhibierung der trombozytenaggregation |
| US7335648B2 (en) | 2003-10-21 | 2008-02-26 | Inspire Pharmaceuticals, Inc. | Non-nucleotide composition and method for inhibiting platelet aggregation |
| US7749981B2 (en) | 2003-10-21 | 2010-07-06 | Inspire Pharmaceuticals, Inc. | Drug-eluting stents coated with non-nucleotide P2Y12 receptor antagonist compound |
| US7825102B2 (en) | 2004-07-28 | 2010-11-02 | Can-Fite Biopharma Ltd. | Treatment of dry eye conditions |
| ES2432113T3 (es) * | 2004-07-28 | 2013-11-29 | Can-Fite Biopharma Ltd. | Agonistas del receptor de adenosina A3 para el tratamiento de trastornos del ojo seco, incluido el síndrome de Sjogren |
| EP1798233A1 (en) * | 2005-12-19 | 2007-06-20 | Faust Pharmaceuticals | Pyrrolo[1,2-a]quinoxaline derivatives as Adenosine A3 receptor modulators and uses thereof |
| EP2227234B1 (en) | 2007-10-15 | 2014-05-07 | Can-Fite Biopharma Ltd. | Method for inducing hepatocyte proliferation and uses thereof |
| WO2010134067A1 (en) | 2009-05-17 | 2010-11-25 | Can-Fite Biopharma Ltd. | A3 adenosine receptor agonists for the reduction of intraocular pressure |
| US9199102B2 (en) | 2009-07-21 | 2015-12-01 | Oradin Pharmaceutical Ltd. | A3 adenosine receptor ligands for modulation of pigmentation |
| US20130045943A1 (en) | 2010-03-03 | 2013-02-21 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of | A3ar agonists for the treatment of uveitis |
| MX378538B (es) | 2012-08-09 | 2025-03-10 | Can Fite Biopharma Ltd | Ligandos del receptor de adenosina a3 para su uso en el tratamiento de una disfuncion sexual. |
| IL242723B (en) | 2015-11-23 | 2019-12-31 | Can Fite Biopharma Ltd | A3 adenosine receptor ligand for the treatment of ectopic fat accumulation |
| IL254535A0 (en) | 2017-09-17 | 2017-11-30 | Can Fite Biopharma Ltd | Adenosine a3 receptor ligand for use in the management of cytokine release syndrome |
| IL264112A (en) | 2019-01-06 | 2020-07-30 | Fishman Pnina | An a3 adenosine receptor ligand for use for reducing level of adipocytes |
| IT202300014340A1 (it) | 2023-07-10 | 2025-01-10 | Consiglio Nazionale Ricerche | Trattamento di malattie associate alla disfunzione del gene ocrl. |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5310731A (en) * | 1984-06-28 | 1994-05-10 | Whitby Research, Inc. | N-6 substituted-5'-(N-substitutedcarboxamido)adenosines as cardiac vasodilators and antihypertensive agents |
| WO1998050047A1 (en) * | 1997-05-09 | 1998-11-12 | Trustees Of The University Of Pennsylvania | Methods and compositions for reducing ischemic injury of the heart by administering adenosine receptor agonists and antagonists |
-
1998
- 1998-07-29 CA CA002296485A patent/CA2296485A1/en not_active Abandoned
- 1998-07-29 JP JP2000504866A patent/JP2003517423A/ja active Pending
- 1998-07-29 AU AU87643/98A patent/AU8764398A/en not_active Abandoned
- 1998-07-29 EP EP98939156A patent/EP1019427A1/en not_active Withdrawn
- 1998-07-29 WO PCT/US1998/016053 patent/WO1999006053A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013516501A (ja) | マイボーム腺機能障害を治療する方法 | |
| CA2798259A1 (en) | Nuclear receptor binding agents | |
| CA2376158A1 (en) | Use of selective estrogen receptor modulators in the manufacture of medicaments for treating and/or suppressing weight gain | |
| JP2006520801A5 (cg-RX-API-DMAC7.html) | ||
| KR20170068629A (ko) | 항코넥신제로서의 플레카이니드의 용도 및 향정신성 약물 효과를 증강시키는 방법 | |
| JP2003509349A5 (cg-RX-API-DMAC7.html) | ||
| MXPA06006696A (es) | (s)-2-n-propilamino-5-hidroxitetralina como un agonista-d3. | |
| KR960041168A (ko) | 베타-아드레날린 효능성 작용물질 | |
| JP4923141B2 (ja) | アデノシン誘導体を有効成分として含有する緑内障治療剤 | |
| JP2004537597A5 (cg-RX-API-DMAC7.html) | ||
| RU2012110380A (ru) | Новое производное 5-фторурацила | |
| JP2017132802A (ja) | ヒストンアセチルトランスフェラーゼ活性剤の使用 | |
| US20110123510A1 (en) | Methods of Affecting Biological Function Through Circadian Clock Feedback Cycle by NAMPT-Mediated NAD+ Biosynthesis | |
| WO2008087461B1 (en) | Use of kynurenic acid and derivatives thereof in the treatment of conditions of the gastrointestinal tract accompanied by hypermotility and inflammation or gout or multiple sclerosis | |
| CN1950076A (zh) | 含安溴索的局部制剂 | |
| CA2464471A1 (en) | Method of treating depression with delta receptor agonist compounds | |
| US20150072935A1 (en) | Composition and external application for acceleration of muscle differentiation and improving of muscle mass | |
| CN1443071A (zh) | 具有神经保护作用的7-β-羟基类固醇 | |
| JP5754885B2 (ja) | 経皮または経粘膜投与用組成物 | |
| JP4246997B2 (ja) | 糖尿病由来虚血性心疾患の治療及び/または予防剤 | |
| CN109310669B (zh) | 氨基甲酸酯化合物用于预防或治疗三叉神经痛的用途 | |
| EP1773307B1 (en) | Compound formulations of 2-amino-1,3-propanediol compounds | |
| JP2000502681A (ja) | 生物学的に活性なベンゾチアゾロンエタンアミン | |
| JP2007518673A5 (cg-RX-API-DMAC7.html) | ||
| US7671091B2 (en) | Penis enlargement |